This study is in progress, not accepting new patients
Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Summary
- Eligibility
- for people ages 18-65 (full criteria)
- Location
- at UCSF
- Dates
- study startedstudy ends around
- Principal Investigator
- by Rebecca Olin (ucsf)
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- Rebecca Olin (ucsf)
Dr. Rebecca Olin is a hematologist who specializes in bone marrow transplantation in adults. Her expertise encompasses treating acute leukemia, myelodysplastic and myeloproliferative disorders (conditions in which the bone marrow makes too many white blood cells) and aplastic anemia (a condition in which the body doesn’t make enough new blood cells).
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Cellectis S.A.
- ID
- NCT03190278
- Phase
- Phase 1 research study
- Study Type
- Interventional
- Participants
- About 29 people participating
- Last Updated